Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

Sanofi pulls Lyxumia’s US filing

Says will resubmit diabetes drug for FDA approval in 2015

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

- PMLiVE

MannKind celebrates as inhaled insulin clears pivotal trials

Closing in on approval of Afrezza

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

- PMLiVE

Novo says three year wait for Tresiba safety data

Trial will start this year comparing insulin’s cardiovascular safety to that of Lantus

- PMLiVE

GSK’s diabetes hope albiglutide delayed in US

FDA extends deadline to April 2014

- PMLiVE

EMA: no new safety concerns with GLP-1 diabetes drugs

CHMP takes issue with study that linked the treatments to serious side effects

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

- PMLiVE

Making mobile health technology work

Augmenting organic life with artificial technology is gaining ground in healthcare

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links